Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Rating of “Moderate Buy” from Brokerages

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.00.

Several research firms have recently issued reports on NBTX. Guggenheim increased their target price on Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. TD Cowen initiated coverage on shares of Nanobiotix in a research report on Friday. They set a “buy” rating on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research report on Tuesday, November 4th.

Nanobiotix Stock Performance

Shares of NASDAQ:NBTX opened at $20.85 on Friday. Nanobiotix has a 12-month low of $2.95 and a 12-month high of $30.35. The business has a 50 day moving average of $21.64 and a 200-day moving average of $17.40.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. purchased a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,356 shares of the company’s stock, valued at approximately $101,000. 38.81% of the stock is currently owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.